Improved glycemic control with insulin aspart: A multicenter randomized double-blind crossover trial in type 1 diabetic patients

Diabetes Care

Volumn 21, Issue 11, 1998, Pages 1904-1909

  Home, Philip D ^a,c   Lindholm, Anders ^b   Hylleberg, Birgitte ^b   Round, Patrick ^b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NOVO NORDISK A S   (Denmark)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN INSULATARD; INSULIN ASPART; NEUTRAL INSULIN; UNCLASSIFIED DRUG;

ADULT; ANOREXIA; ARTICLE; CLINICAL TRIAL; CROSSOVER PROCEDURE; DETERIORATION; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG FORMULATION; FATIGUE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; VOMITING;

ADULT; BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; CIRCADIAN RHYTHM; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FRUCTOSAMINE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; POSTPRANDIAL PERIOD;

EID: 0031784260     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.21.11.1904     Document Type: Article

References (27)

1. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and the progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
2. Reichard P, Nilsson BY, Rosenqvist U: The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 329:304-339, 1993
3. Wiseman MJ, Saunders AJ, Keen H, Viberti GC: Effect of blood glucose control on increased glomerular filtration rate and kidney size in insulin-dependent diabetes. N Engl J Med 312:617-621, 1985
4. Wang PH, Lau J, Chalmers TC: Meta-analysis of effects of intensive blood-glucose control on late complications of type 1 diabetes. Lancet 341:1306-1309, 1993
5. Binder C: Absorption of injected insulin. Acta Pharmacol Toxicol 27 (Suppl. 2): 1-84, 1969
6. Binder C, Lauritzen T, Faber O, Pramming S: Insulin pharmacokinetics, Diabetes Care 7:188-199, 1984
7. Owens DR: Human insulin. Lancaster, U.K., MTP, 1986
8. Home PD: Insulin therapy. In The International Textbook of Diabetes, 2nd ed. Alberti KGMM, Zimmet P, DeFronzo RA, Eds. Chichester, U.K., Wiley, 1996, p. 899-928
9. Hirsch IB, Farkas-Hirsch R, Skyler JS: Intensive insulin therapy for treatment of type I diabetes. Diabetes Care 13:1265-1283, 1990
10. Blundell T, Dodson G, Hodgkin D, Mercola D: Insulin: the structure in the crystal and its reflection in chemistry and biology. Adv Protein Chem 26:279-402, 1972
11. Brange J, Ribel U, Hansen JF, Dodson G, Hansen MY, Havelund S, Melberg SG, Morris F, Noons K, Snel L, Sörensen AR, Voigt HO: Monomeric insulins obtained by protein engineering and their medical implications. Nature 333:679-682, 1988
12. B28) on meal-related plasma glucose excursions in type I diabetic subjects. Diabetes Care 14:571-577, 1991
13. Lutterman JA, Pijpers E, Netten PM, Jørgensen LN: Glycaemic control in IDDM patients during one day with injection of human insulin or the insulin analogues insulin X14 and insulin X14(+Zn). In Frontiers in Insulin Pharmacology. Berger M, Gries FA, Eds. Stuttgart, Germany, Thieme, 1993, p. 102-109
14. Wiefels K, Kuglin B, Hübinger A, Jørgensen LN. Gries FA: Insulin kinetics and dynamics in insulin-dependent diabetic patients after injection of human insulin or the insulin analogues X14 and X14 + Zn. In Frontiers in Insulin Pharmacology. Berger M, Cries FA. Eds. Stuttgart, Germany, Thieme, 1993, p. 97-101
15. Heinemann L, Kapitza C, Starke AAR, Heise T: Time-action profile of the insulin analogue B28Asp. Diabet Med 13:683-684, 1996
16. Drejer K: The bioactivity of insulin analogues from in vitro receptor binding to in vivo glucose uptake. Diabetes Metab Rev 8:259-286, 1992
17. Holleman F, Hoekstra JBL: Insulin lispro. N Engl J Med 337:176-183, 1997
18. Jorgensen LN, Nielsen FS: Timing of pre-meal insulins in diabetic patients on a multiple daily injection regimen: a questionnaire study (Abstract). Diabetologa 33 (Suppl. 1):A116, 1990
19. Berger M, Heinemann L: Are presently available insulin analogues clinically beneficial? Diabet Med 40 (Suppl. 2):S91-S96, 1997
20. Heinemann L: Do insulin-treated diabetic patients use an injection-meal-interval in daily life? Diabet Med 12:449-450, 1995
21. Heinemann L, Starke AAR, Hohmann A, Berger M: Timing between the subcutaneous administration of insulin and consumption of a carbohydrate rich meal. Harm Metab Res 10 (Suppl. 26):137-139, 1992
22. Howey DC, Bowsher RR, Brunelle RL, Rowe HM, Santa PF, Downing-Shelton J, Woodworth JR: [Lys(B28), Pro(B29)]-human insulin: effect of injection time on postprandial glycaemia. Clin Pharmacol Ther 58:459-469, 1995
23. Anderson JH Jr, Brunelle RL, Koivisto VA, Pfützner A, Trautmann ME, Vignati L, DiMarchi R: Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment: Multicenter Insulin Lispro Study Group, Diabetes 46:265-270, 1997
24. Zinman B, Tildesley H. Chiasson JL, Tsui E, Strack TR: Insulin lispro in CSII: results of a double-blind crossover study. Diabetes 46:440-443, 1997
25. Rowe R, Anderson JH, Gale E: A double-blind comparison of insulin lispro and regular insulin in patients on a multiple injection regimen (Abstract). Diabetes 45 (Suppl. 2):71A, 1996
26. Torlone E, Pampanelli S, Lalli C, Del Sindaco P, Di Vincenzo A, Rambotti AM, Modarelli F, Epifano L, Kassi G, Perriello G, Brunetti P, Bolli G: Effects of the short-acting insulin analog [Lys(B28), Pro(B29)] on postprandial blood glucose control in IDDM. Diabetes Care 19:945-952, 1996
27. Ahmed ABE, Home PD: The effect of the insulin analog lispro on nighttime blood glucose control in type 1 diabetic patients. Diabetes Care 21:32-37, 1998